🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥CROWN: Characterizing Resistance Mechanisms and Predictors of Early Progression and Long-Term Response to Lorlatinib: Circulating Tumor DNA (ctDNA) Analyses From the CROWN Study 🎙️ @bensolomon1 🔢2636RO 🎯No New On-Target ALK Resistance Mutations 🎯Bypass (RTK/RAS/MAPK) Pathways Drive Resistance; Baseline Genomic Complexity Higher in Early Progressors 🎯On-Treatment TF Drop Predicts Longer PFS ☑️NCT03052608 🔗 https://t.co/E2MIRGnkpb @OncoAlert @Larvol @myESMO @IASLC @ALKpositiveINT